Heineken GLP 1 warning tells UK pubs to plan for fewer pints

Heineken has told British pubs and bars that the spread of GLP 1 weight loss drugs could cut sales of beer and cider. The Heineken GLP 1 warning came in a presentation sent to hospitality customers this month, first reported by Reuters and detailed by The Guardian on 23 October. The brewer said users may want fewer drinks and smaller serves. It urged venues to push half pints, low and no alcohol options and food pairings. Rival brewers disagree on the size of the effect, and the clinical evidence comes mainly from studies of problem drinking.

What Heineken told British pubs

According to The Guardian, the presentation said GLP 1 medicines such as Ozempic and Wegovy can reduce the urge to drink alcohol. That, the brewer argued, could mean what it called "fullness and fewer serves" in pubs and bars. The document suggested that long sessions of several pints in a row could become less common. Heineken advised venues to promote half pints, stock more low and zero alcohol drinks and pair drinks with small plates of food. Without such changes, the presentation warned, outlets risk fewer visits and lower spending per customer. Heineken said it shared the material as part of its regular contact with British trade customers about how drinking habits are changing.

A company spokesperson framed the shift as one trend among several. "We see some changes in consumption behaviour among (GLP-1) users and will continue to monitor how these behaviours evolve in 2027," the spokesperson said. The brewer has identified a preference for smaller serves, lower strength drinks and more premium products among people taking the drugs. "Our latest consumer research suggests GLP-1 users are not simply replacing alcohol," the spokesperson added, describing users as more purposeful in their choices. Heineken also said these habits are not unique to people on the medicines and reflect a wider move toward moderation and health. The company owns Amstel, Sol and Strongbow cider alongside its own lager brand, so the Heineken GLP 1 advice reaches venues that pour many of its products.

How big the market at stake is

Heineken put the value of beer sold in British pubs, bars and restaurants at almost 14 billion pounds in the year to February. Less than 300 million pounds of that came from low and no alcohol products, by the brewer's own count. Those figures show both the exposure and the gap. Even a small change in the number of pints per visit would touch a large sum, while the alternative products Heineken is promoting remain a small part of the trade. The Guardian cited research by JP Morgan that 10 million people in the United States used the medicines last year. Comparable British usage figures were not given in the report, and Heineken did not say how many of its customers it expects to be affected.

"We see some changes in consumption behaviour among (GLP-1) users and will continue to monitor how these behaviours evolve in 2027," the spokesperson said.

The rest of the drinks industry is split on how much the drugs matter. The Guardian reported that Diageo, which makes Guinness, has told investors that any impact from wider use of the medicines should be manageable. Carlsberg told Reuters that its data did not support the idea that weight loss drugs were changing beer consumption trends. Surveys from market research firms Circana, NIQ and KAM have pointed to lower drinking among users. None of these company statements or surveys is a controlled study, and they do not separate the effect of the drugs from other forces such as price, health trends and changing social habits. Our industry desk tracks how drug makers and other sectors respond to these medicines.

What the clinical evidence shows on alcohol

The strongest data come from people with alcohol use disorder, not from typical pub customers. A Danish trial published in The Lancet in May 2026 randomly assigned 108 adults with moderate to severe alcohol use disorder and obesity to weekly semaglutide or placebo for 26 weeks. All participants also received cognitive behavioural therapy. Heavy drinking days fell by 41.1 percentage points from baseline in the semaglutide group and by 26.4 points on placebo. The difference of 13.7 points was statistically significant. In total, 81% of participants completed the full course. Side effects were mostly mild or moderate stomach problems and were more common with semaglutide. Funders included the Novo Nordisk Foundation, which controls Wegovy's maker.

That trial tested a specific group seeking treatment, so its results cannot be applied directly to social drinkers. Semaglutide is not approved for alcohol use disorder, and the trial was conducted at a single centre. The Lancet paper adds to earlier animal and small human studies that pointed in the same direction. A reader weighing claims about drug effects on drinking can use our guide to reading a weight-loss trial headline, since the same questions apply: who was studied, against what comparison and for how long. The Heineken GLP 1 presentation itself is commercial advice based on consumer research, and its methods have not been published for outside review.

What comes next for brewers and drug makers

Heineken said it will keep watching how user behaviour develops through 2027. Pubs that follow its advice may shift menus toward smaller measures and alcohol free lines, but the presentation does not show whether that would offset lower volumes. Drug makers are widening access at the same time. An oral version of Wegovy is already on sale in the United States and the United Kingdom, a step covered in our report on the first GLP 1 pill for weight management. A daily tablet could reach people who avoid injections, which would add to the pool of users that brewers are trying to measure.

Several questions remain open. Neither the brewer nor the press reports cite a large study of how GLP 1 use changes ordinary drinking in pubs over years rather than months. The brewers' own data sets are not public, and their conclusions differ. It is also unclear how many users keep taking the medicines long term, which would shape any lasting effect on alcohol sales. Regulators have not approved any GLP 1 drug to reduce drinking, so any change in alcohol use remains a side effect rather than a goal of treatment. Larger trials in more varied groups would be needed to show whether the Danish findings hold beyond a single clinic.

Conclusion

The Heineken GLP 1 warning shows a major brewer planning for fewer pints per visit as weight loss drugs spread. The company's evidence is consumer research, not published data, and rivals Diageo and Carlsberg see a smaller or no effect. The only controlled data come from a Danish trial in alcohol use disorder. For now, the effect on ordinary drinking remains a forecast, not a measured fact.